statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink...

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Karyopharm Therapeutics Inc. (NASDAQ:KPTI  Free Report)  Equities researchers at Leerink Partnrs issued their Q1 2024 EPS estimates for Karyopharm Therapeutics in a research report...

Leerink Partnrs Weighs in on Karyopharm Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI  Free Report) had its price objective lowered by HC Wainwright from $10.00 to $8.00 in a report issued on Friday morning, Benzinga reports. The firm...

HC Wainwright Trims Karyopharm Therapeutics (NASDAQ:KPTI) Target Price to $8.00

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights...

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Image source: The Motley Fool.Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ETOperatorContinue reading...

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript...

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 PR Newswire...

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Barclays PLC raised its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI  Free Report) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Bought by Barclays PLC

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Volume	34,333.00
52-Wk High	$3.87
52-Wk Low	$0.6174

KPTI Karyopharm Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals